EBGLYSS is an interleukin-13 antagonist indicated for the treatment of adult and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.<\/p>\n
EBGLYSS (lebrikizumab-lbkz), injection, for subcutaneous use Initial U.S. Approval: 2024<\/p>\n
If EBGLYSS (lebrikizumab-lbkz) are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN.<\/strong> For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query.\u00a0To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/strong><\/p>\n Note:<\/strong><\/em> <\/p>\n","protected":false},"excerpt":{"rendered":" Ebglyss is a medicine used to treat moderate to severe atopic dermatitis (also known as atopic eczema, when the skin is itchy, red and dry). It is used in adults and children aged 12 years and over weighing at least 40 kg. It is used in patients for whom treatment applied directly to the skin cannot be used or is not sufficient.\u00a0Ebglyss contains the\u00a0active substance<\/span>\u00a0lebrikizumab.<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient. Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a><\/strong>. With over two decades of industry experience, IPN offers extensive coverage across India, including prominent cities such as\u00a0Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik,<\/strong>\u00a0and various other regions in India.<\/em><\/p>\nBrand Name: EBGLYSS\u00a0 Generic Name: lebrikizumab-lbkz . EBGLYSS (lebrikizumab-lbkz) is used to treat atopic dermatitis (also known as atopic eczema).<\/h2>\n